54 related articles for article (PubMed ID: 20715420)
41. Ubiquitylation-independent ER-associated degradation of an AE1 mutant associated with dominant hereditary spherocytosis in cattle.
Ito D; Koshino I; Arashiki N; Adachi H; Tomihari M; Tamahara S; Kurogi K; Amano T; Ono K; Inaba M
J Cell Sci; 2006 Sep; 119(Pt 17):3602-12. PubMed ID: 16912075
[TBL] [Abstract][Full Text] [Related]
42. Lumenal localization in the endoplasmic reticulum of the C-terminal tail of an AE1 mutant responsible for hereditary spherocytosis in cattle.
Ito D; Otsuka Y; Koshino I; Inaba M
Jpn J Vet Res; 2007 Feb; 54(4):191-7. PubMed ID: 17405356
[TBL] [Abstract][Full Text] [Related]
43. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator.
Namkung W; Kim KH; Lee MG
Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066
[TBL] [Abstract][Full Text] [Related]
44. Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain 1 (NBD-1) and CFTR truncated within NBD-1 target to the epithelial plasma membrane and increase anion permeability.
Clancy JP; Hong JS; Bebök Z; King SA; Demolombe S; Bedwell DM; Sorscher EJ
Biochemistry; 1998 Oct; 37(43):15222-30. PubMed ID: 9790686
[TBL] [Abstract][Full Text] [Related]
45. Improved maturation of CFTR by an ER export signal.
Wendeler MW; Nufer O; Hauri HP
FASEB J; 2007 Aug; 21(10):2352-8. PubMed ID: 17392477
[TBL] [Abstract][Full Text] [Related]
46. The forced aggresome formation of a bovine anion exchanger 1 (AE1) mutant through association with δF508-cystic fibrosis transmembrane conductance regulator upon proteasome inhibition in HEK293 cells.
Adachi H; Kurooka T; Otsu W; Inaba M
Jpn J Vet Res; 2010 Aug; 58(2):101-10. PubMed ID: 20715420
[TBL] [Abstract][Full Text] [Related]
47. What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Meiners S; Eickelberg O
Eur Respir J; 2012 Nov; 40(5):1260-8. PubMed ID: 22441749
[TBL] [Abstract][Full Text] [Related]
48.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
49.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
50.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
51.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
